

Pepinemab Antibody Platform (anti-Semaphorin 4D Mab)

Oncology

Pepinemab COMBO with pembrolizumab in first-line R/M HNSCC (with Merck US)

KEYNOTE B84

COMPLETE

Pepinemab COMBO with avelumab in NSCLC (Collaboration with Merck KGaA, Darmstadt, Germany)

CLASSICAL-Lung

Pepinemab COMBO in Multiple “Window of Opportunity” Studies, HNSCC, Melanoma, PDAC

Multiple IST sponsored by Emory University, Winship Cancer Institute

Neurology

Pepinemab in Huntington’s Disease (Orphan Drug and Fast Track Designations)

COMPLETE

SIGNAL

Pepinemab in Alzheimer’s Disease

SIGNAL-AD

ActivMAb® Antibody Platform

Complex Membrane Protein expression, Ab Discovery, Target ID

VX5 (anti-CXCL13 MAb) for Autoimmune Diseases